

Psoriasis Market to witness growth by 2032, estimates DelveInsight

Psoriasis Companies are Biohaven, Bristol-Myers Squibb, UCB Pharma, Janssen, Novartis, Pfizer, Boehringer Ingelheim, AbbVie, Aclaris, others.

ALBANY, NEW YORK, UNITED STATES, April 4, 2024 /EINPresswire.com/ -- DelveInsight's "Psoriasis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Psoriasis, historical and forecasted epidemiology as well as the Psoriasis market trends

in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Psoriasis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Psoriasis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Psoriasis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Psoriasis market.

Request for a Free Sample Report @ [Psoriasis Market Forecast](#)

Some facts of the Psoriasis Market Report are:

- According to DelveInsight, Psoriasis market size is expected to grow at a decent CAGR by 2032.
- Leading Psoriasis companies working in the market are Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb, Ventyx Biosciences, Inc, Amgen, AbbVie, Alumis Inc, DICE Therapeutics, Inc., UCB Pharma, Janssen Research & Development, LLC, Arcutis Biotherapeutics, Inc., AnaptysBio, Inc., Sun Pharmaceutical Industries Limited, Novartis, Pfizer, Boehringer Ingelheim, KoBioLabs, Abcentra, Aclaris Therapeutics, and others
- Key Psoriasis Therapies expected to launch in the market are TLL018 tablets, Rimegepant, SFA002, BMS-986165, BMS-986322, VTX958, Apremilast, Risankizumab, ESK-001, DC-806, Bimekizumab, JNJ-77242113, Topical roflumilast, Imsidolimab, Tildrakizumab, Secukinumab, PF-07038124, Spesolimab, KBL697, Orticumab, ATI-450, and others.



- In January 2023, SFA Therapeutics announced that the US FDA cleared to proceed with an extension to the ongoing Phase Ib clinical trial of SFA-002 for psoriasis. The trial is expected to complete by September 2023.

Psoriasis Overview

Psoriasis is a chronic autoimmune condition that accelerates the growth cycle of skin cells, resulting in the formation of thick, red patches with silvery scales. It commonly affects the skin on the elbows, knees, scalp, and lower back, although it can appear anywhere on the body. The exact cause is not fully understood, but genetic and environmental factors are believed to play a role. Symptoms include itching, pain, and cracked skin, and in severe cases, psoriasis can affect nails and joints, leading to psoriatic arthritis. Diagnosis is usually based on physical examination and medical history. Treatment options vary depending on the severity and may include topical treatments, phototherapy, oral medications, and biologic therapies targeting the immune system. While psoriasis is not curable, symptoms can often be managed effectively with appropriate treatment, leading to improved quality of life for those affected. Regular monitoring and medical care are typically necessary to control the condition.

Learn more about Psoriasis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/psoriasis-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr

Psoriasis Market

The Psoriasis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Psoriasis market trends by analyzing the impact of current Psoriasis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Psoriasis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Psoriasis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Psoriasis market in 7MM is expected to witness a major change in the study period 2019-2032.

Psoriasis Epidemiology

The Psoriasis epidemiology section provides insights into the historical and current Psoriasis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Psoriasis market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Psoriasis Epidemiology @ [Psoriasis Market Dynamics and Trends](#)

Psoriasis Drugs Uptake

This section focuses on the uptake rate of the potential Psoriasis drugs recently launched in the Psoriasis market or expected to be launched in 2019-2032. The analysis covers the Psoriasis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Psoriasis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Psoriasis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Psoriasis Pipeline Development Activities

The Psoriasis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Psoriasis key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Psoriasis pipeline development activities @ [Psoriasis Therapies and Drugs](#)

Psoriasis Therapeutics Assessment

Major key companies are working proactively in the Psoriasis Therapeutics market to develop novel therapies which will drive the Psoriasis treatment markets in the upcoming years are Hangzhou HighlightII Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb, Ventyx Biosciences, Inc, Amgen, AbbVie, Alumis Inc, DICE Therapeutics, Inc., UCB Pharma, Janssen Research & Development, LLC, Arcutis Biotherapeutics, Inc., AnaptysBio, Inc., Sun Pharmaceutical Industries Limited, Novartis, Pfizer, Boehringer Ingelheim, KoBioLabs, Abcentra, Aclaris Therapeutics, and others.

Psoriasis Report Key Insights

1. Psoriasis Patient Population
2. Psoriasis Market Size and Trends
3. Key Cross Competition in the Psoriasis Market
4. Psoriasis Market Dynamics (Key Drivers and Barriers)
5. Psoriasis Market Opportunities
6. Psoriasis Therapeutic Approaches
7. Psoriasis Pipeline Analysis
8. Psoriasis Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Psoriasis Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Psoriasis Competitive Intelligence Analysis

4. Psoriasis Market Overview at a Glance
5. Psoriasis Disease Background and Overview
6. Psoriasis Patient Journey
7. Psoriasis Epidemiology and Patient Population
8. Psoriasis Treatment Algorithm, Current Treatment, and Medical Practices
9. Psoriasis Unmet Needs
10. Key Endpoints of Psoriasis Treatment
11. Psoriasis Marketed Products
12. Psoriasis Emerging Therapies
13. Psoriasis Seven Major Market Analysis
14. Attribute Analysis
15. Psoriasis Market Outlook (7 major markets)
16. Psoriasis Access and Reimbursement Overview
17. KOL Views on the Psoriasis Market
18. Psoriasis Market Drivers
19. Psoriasis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Ankit Nigam

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/701054860>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.